{"id":804,"date":"2025-11-24T22:33:57","date_gmt":"2025-11-24T22:33:57","guid":{"rendered":"http:\/\/interrogacao.org\/?p=804"},"modified":"2025-11-24T22:33:57","modified_gmt":"2025-11-24T22:33:57","slug":"this-may-be-a-sufficient-strategy-for-a-well-tolerated-drug-candidate","status":"publish","type":"post","link":"https:\/\/interrogacao.org\/?p=804","title":{"rendered":"\ufeffThis may be a sufficient strategy for a well-tolerated drug candidate"},"content":{"rendered":"<p>\ufeffThis may be a sufficient strategy for a well-tolerated drug candidate. passive leak is dwarfed by brain accumulation of endothelial-targeted agents: At 4 hours after injury, anti-PECAM mAbs accumulate at 8-fold higher levels in the brain vs. nonimmune IgG; anti-VCAM nanoparticles (NPs) deliver a protein therapeutic (superoxide dismutase, SOD) at 4.5-fold higher levels than the carrier-free therapeutic at 24 hours after injury. These data suggest that relying on passive vascular leak provides inefficient delivery Shikonin of therapeutics even at early time points after ICH, and that a better strategy might be targeted delivery to the brain endothelium, Shikonin which serves as the gateway for the immune attack within the peri-hemorrhage inflamed mind region. Keywords:intracerebral hemorrhage, endothelial swelling, targeted nanoparticles, <a href=\"https:\/\/www.adooq.com\/shikonin.html\">Shikonin<\/a> vascular leakage, mind drug delivery, hemorrhagic stroke == Graphical Abstract == == Description: == In experimental intracerebral hemorrhage (ICH), endothelial focusing on is an advantageous mind delivery strategy actually during high vascular leakage (early ICH). This advantage increases with time, as vascular leakage resolves. == Intro == Spontaneous intracerebral hemorrhages (ICH) account for up to 25% percent of all strokes[1]. Although less frequent than ischemic stroke, ICH causes higher disability and the 30-day time mortality is definitely up to 50% [2]. Global incidence is definitely ~24.6 per 100,000 person-years [1], and likely higher in the US [3]. Initial symptoms can be non-specific (i.e., headache, confusion), so ICH individuals often present to care after 24 hours from onset [48]. Hematoma expansion can occur within 6 hours from sign onset [913] Shikonin with up to 20% additional hematoma growth happening in the 1st 24 hours [4,14]. Beyond supportive interventions like blood pressure [3,15], you will find no directed therapies that improve results in ICH. Most ICHs are from arterial bleeds in deep mind structures, likely due to hypertensive angiopathy [35,7]. The initial phase of injury in ICH is likely due to mass effect from your hematoma and connected edema. Among secondary mechanisms of injury, neurovascular swelling is considered a key driver, leading to microglial activation and recruitment of peripheral immune cells, likely due to endothelial activation [16,17]. Specifically, this recruitment of peripheral immune cells requires adhesion molecules such as platelet endothelial adhesion molecule (PECAM), intercellular adhesion molecule (ICAM), and vascular cell adhesion molecule (VCAM) [16,1821]. Although immune cell populations have complex functions in ICH, medical data suggests that neurovascular swelling is detrimental in ICH [22], and regulators of endothelial activation like VCAM and ICAM could be fascinating focuses on for restorative delivery. For many mind diseases, targeted drug delivery has been challenged from the blood-brain barrier (BBB) [2326]. Although targeted delivery for ICH (including use of NPs) has been explored in preclinical investigations [2729], large clinical tests in ICH have relied on passive delivery to the brain [3033], likely assuming that vascular leakage will become adequate to allow <a href=\"http:\/\/avalon.law.yale.edu\/19th_century\/emancipa.asp\"> SCC3B<\/a> build up of candidate therapeutics at the site of injury, especially early in the injury. However, targeted therapies for ICH may steer clear of the problem of mind delivery by focusing on the accessible inflamed mind endothelium for drug delivery. Here we test the hypothesis that mind drug delivery can rely on passive delivery from continued arterial bleed, informed by medical data concerning timing of hematoma growth. We use an established model for experimental ICH [34,35], striatal injection of collagenase [3436] in mice, which recapitulates the most common form of ICH by causing a bleed in deep mind constructions. With this model, we explore Shikonin whether drug delivery can be achieved by passive leak vs targeted endothelial delivery over time after ICH. Remarkably, we find drug delivery via passive leak halts early. We then solve the delivery problem by using NPs to target a candidate drug to the brain endothelium, a key entry point for leukocyte infiltration into the ICH bed. == Results == == Vascular permeability in experimental intracerebral hemorrhage.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>\ufeffThis may be a sufficient strategy for a well-tolerated drug candidate. passive leak is dwarfed by brain accumulation of endothelial-targeted agents: At 4 hours after injury, anti-PECAM mAbs accumulate at 8-fold higher levels in the brain vs. nonimmune IgG; anti-VCAM nanoparticles (NPs) deliver a protein therapeutic (superoxide dismutase, SOD) at 4.5-fold higher levels than the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[],"class_list":["post-804","post","type-post","status-publish","format-standard","hentry","category-transforming-growth-factor-beta-receptors"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\ufeffThis may be a sufficient strategy for a well-tolerated drug candidate - Current concepts in The identification and characterisation of Rho Kinase Inhibitors<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/interrogacao.org\/?p=804\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\ufeffThis may be a sufficient strategy for a well-tolerated drug candidate - Current concepts in The identification and characterisation of Rho Kinase Inhibitors\" \/>\n<meta property=\"og:description\" content=\"\ufeffThis may be a sufficient strategy for a well-tolerated drug candidate. passive leak is dwarfed by brain accumulation of endothelial-targeted agents: At 4 hours after injury, anti-PECAM mAbs accumulate at 8-fold higher levels in the brain vs. nonimmune IgG; anti-VCAM nanoparticles (NPs) deliver a protein therapeutic (superoxide dismutase, SOD) at 4.5-fold higher levels than the [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/interrogacao.org\/?p=804\" \/>\n<meta property=\"og:site_name\" content=\"Current concepts in The identification and characterisation of Rho Kinase Inhibitors\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-24T22:33:57+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/interrogacao.org\\\/?p=804#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/interrogacao.org\\\/?p=804\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/interrogacao.org\\\/#\\\/schema\\\/person\\\/9d902a39920e069aa8351f1dcc7f042c\"},\"headline\":\"\ufeffThis may be a sufficient strategy for a well-tolerated drug candidate\",\"datePublished\":\"2025-11-24T22:33:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/interrogacao.org\\\/?p=804\"},\"wordCount\":617,\"articleSection\":[\"Transforming Growth Factor Beta Receptors\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/interrogacao.org\\\/?p=804\",\"url\":\"https:\\\/\\\/interrogacao.org\\\/?p=804\",\"name\":\"\ufeffThis may be a sufficient strategy for a well-tolerated drug candidate - Current concepts in The identification and characterisation of Rho Kinase Inhibitors\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/interrogacao.org\\\/#website\"},\"datePublished\":\"2025-11-24T22:33:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/interrogacao.org\\\/#\\\/schema\\\/person\\\/9d902a39920e069aa8351f1dcc7f042c\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/interrogacao.org\\\/?p=804#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/interrogacao.org\\\/?p=804\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/interrogacao.org\\\/?p=804#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/interrogacao.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\ufeffThis may be a sufficient strategy for a well-tolerated drug candidate\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/interrogacao.org\\\/#website\",\"url\":\"https:\\\/\\\/interrogacao.org\\\/\",\"name\":\"Current concepts in The identification and characterisation of Rho Kinase Inhibitors\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/interrogacao.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/interrogacao.org\\\/#\\\/schema\\\/person\\\/9d902a39920e069aa8351f1dcc7f042c\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84f70ab93180dc5fbd16f7ba36d369a0d5f4b4bfcf63033e4e5585f4ac0c1317?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84f70ab93180dc5fbd16f7ba36d369a0d5f4b4bfcf63033e4e5585f4ac0c1317?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84f70ab93180dc5fbd16f7ba36d369a0d5f4b4bfcf63033e4e5585f4ac0c1317?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"sameAs\":[\"http:\\\/\\\/interrogacao.org\"],\"url\":\"https:\\\/\\\/interrogacao.org\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\ufeffThis may be a sufficient strategy for a well-tolerated drug candidate - Current concepts in The identification and characterisation of Rho Kinase Inhibitors","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/interrogacao.org\/?p=804","og_locale":"en_US","og_type":"article","og_title":"\ufeffThis may be a sufficient strategy for a well-tolerated drug candidate - Current concepts in The identification and characterisation of Rho Kinase Inhibitors","og_description":"\ufeffThis may be a sufficient strategy for a well-tolerated drug candidate. passive leak is dwarfed by brain accumulation of endothelial-targeted agents: At 4 hours after injury, anti-PECAM mAbs accumulate at 8-fold higher levels in the brain vs. nonimmune IgG; anti-VCAM nanoparticles (NPs) deliver a protein therapeutic (superoxide dismutase, SOD) at 4.5-fold higher levels than the [&hellip;]","og_url":"https:\/\/interrogacao.org\/?p=804","og_site_name":"Current concepts in The identification and characterisation of Rho Kinase Inhibitors","article_published_time":"2025-11-24T22:33:57+00:00","author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/interrogacao.org\/?p=804#article","isPartOf":{"@id":"https:\/\/interrogacao.org\/?p=804"},"author":{"name":"admin","@id":"https:\/\/interrogacao.org\/#\/schema\/person\/9d902a39920e069aa8351f1dcc7f042c"},"headline":"\ufeffThis may be a sufficient strategy for a well-tolerated drug candidate","datePublished":"2025-11-24T22:33:57+00:00","mainEntityOfPage":{"@id":"https:\/\/interrogacao.org\/?p=804"},"wordCount":617,"articleSection":["Transforming Growth Factor Beta Receptors"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/interrogacao.org\/?p=804","url":"https:\/\/interrogacao.org\/?p=804","name":"\ufeffThis may be a sufficient strategy for a well-tolerated drug candidate - Current concepts in The identification and characterisation of Rho Kinase Inhibitors","isPartOf":{"@id":"https:\/\/interrogacao.org\/#website"},"datePublished":"2025-11-24T22:33:57+00:00","author":{"@id":"https:\/\/interrogacao.org\/#\/schema\/person\/9d902a39920e069aa8351f1dcc7f042c"},"breadcrumb":{"@id":"https:\/\/interrogacao.org\/?p=804#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/interrogacao.org\/?p=804"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/interrogacao.org\/?p=804#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/interrogacao.org\/"},{"@type":"ListItem","position":2,"name":"\ufeffThis may be a sufficient strategy for a well-tolerated drug candidate"}]},{"@type":"WebSite","@id":"https:\/\/interrogacao.org\/#website","url":"https:\/\/interrogacao.org\/","name":"Current concepts in The identification and characterisation of Rho Kinase Inhibitors","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/interrogacao.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/interrogacao.org\/#\/schema\/person\/9d902a39920e069aa8351f1dcc7f042c","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/84f70ab93180dc5fbd16f7ba36d369a0d5f4b4bfcf63033e4e5585f4ac0c1317?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/84f70ab93180dc5fbd16f7ba36d369a0d5f4b4bfcf63033e4e5585f4ac0c1317?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/84f70ab93180dc5fbd16f7ba36d369a0d5f4b4bfcf63033e4e5585f4ac0c1317?s=96&d=mm&r=g","caption":"admin"},"sameAs":["http:\/\/interrogacao.org"],"url":"https:\/\/interrogacao.org\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/interrogacao.org\/index.php?rest_route=\/wp\/v2\/posts\/804","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/interrogacao.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/interrogacao.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/interrogacao.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/interrogacao.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=804"}],"version-history":[{"count":1,"href":"https:\/\/interrogacao.org\/index.php?rest_route=\/wp\/v2\/posts\/804\/revisions"}],"predecessor-version":[{"id":805,"href":"https:\/\/interrogacao.org\/index.php?rest_route=\/wp\/v2\/posts\/804\/revisions\/805"}],"wp:attachment":[{"href":"https:\/\/interrogacao.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=804"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/interrogacao.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=804"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/interrogacao.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=804"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}